Investigation of microemulsion system for transdermal delivery of itraconazole

Journal of Advanced Pharmaceutical Technology and Research

Volumn 2, Issue 1, 2011, Pages 30-38

  Chudasama, Arpan ^a   Patel, Vineetkumar ^a   Nivsarkar, Manish ^a   Vasu, Kamala ^a   Shishoo, Chamanlal ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Antifungal; microemulsion; permeability; phase diagram; transdermal

Indexed keywords

ITRACONAZOLE;

ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; MICROEMULSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SKIN IRRITATION; TRANSDERMAL PATCH; VISCOSITY;

EID: 79955751904     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.79802     Document Type: Article

References (57)

1. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14:S161-9.
2. Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992;14:S43-53.
3. Grant SM, Clissold SP. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superfi cial and systemic mycoses. Drugs 1989;37:310-44. (Pubitemid 19083614)
4. Lortholary O, Denning DW, Dupont B. Endemic mycoses: A treatment update. J Antimicrob Chemother 1999;43:321-31. (Pubitemid 29121870)
5. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole: Pharmacologic studies in animals and humans. Rev Infect Dis 1987;9:S43-6.
6. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrij sen K, et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989;32:67-87.
7. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9:S94-99.
8. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988;31:476-85.
9. Dupont B. Itraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol 1990;23:607-14. (Pubitemid 20263688)
10. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72. (Pubitemid 24034139)
11. Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 1991;28:555-60.
12. Thomson PDR, Montvale NJ. 59th ed. Montavale, NJ. Physician's Desk Reference;2005. p. 1757-66.
13. Schaefer H, Redelmeier TE. Prediction and measurements of percutaneous absorption. In: Schaefer H, Redelmeier TE, editors. Skin Barrier: principles of percutaneous absorption. Basel, Karge, 1996. p. 118-52.
14. Ghosh TK, Pfi ster WR, Yum SI, editors. Transdermal and Topical Drug Delivery Systems, Interpharm Press, Buff alo Grove, IL. 1997. p. 33-112
15. Odds FC, Van Custem J. Itraconazole: Preclinical data in vitro and in vivo in cutaneous and other superfi cial mycoses. Clin Dermatol 1993;7:251-61.
16. Gupta AK, Neil NH. A risk-benefi t assessment of the newer oral antifungal agents used to treat onchomycosis. Drug Saf 2000; 22:33-52. (Pubitemid 30058026)
17. Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol 2002;3:71-81. (Pubitemid 34261188)
18. Tenjarla S. Microemulsions: An overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 1999;16:461-521. (Pubitemid 30004629)
19. Ktistis G, Niopas I. A study on the in-vitro percutaneous absorption of propranolol from disperse systems. J Pharm Pharmacol 1998;50:413-8. (Pubitemid 28197419)
20. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterization and transdermal drug delivery potential of microemulsion systems. J Control Release 2000;69:421-33.
21. Gasco MR, Gallarate M, Pattarino F. In vitro permeation of azelaic acid from viscosized microemulsions. Int J Pharm 1991;69:193-6.
22. Kriwet K, Muller-Goymann CC. Diclofenac release from phospholipid drug systems and permeation through excised human stratum corneum. Int J Pharm 1995;125:231-42.
23. Edwards JEJ. Candida species. In: Mandell GL, BennettJE, Dolin JE, editors. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, Inc; 1995. p. 2289-306.
24. Guidelines of care for superfi cial mycotic infections of the skin: Mucocutaneous candidiasis. Guidelines/Outcome Committee. American Academy of Dermatology. J Am Acad Dermatol 1996;34:110-5.
25. Elmets CA. Management of common superfi cial fungal infections in patients with AIDS. J Am Acad Dermatol 1994;31:S60-3. (Pubitemid 24280350)
26. Yoo SD, Kang EH, Jun H, Shin BS, Lee KC, Lee KH. Absorption, First- pass metabolism, and disposition of itraconazole in rats. Chem Pharm Bull 2000;48:798-801. (Pubitemid 30430115)
27. Shim SY, Ji CW, Sah H, Par ES, Lee BJ. Characterization of itraconazole semisolid dosage forms prepared by hot melt technique. Arch Pharm Res 2006;29:1055-60. (Pubitemid 44885785)
28. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 2008;361:177-88.
29. Djordjevic L, Primorac M, Stupar M, Krajisnik D. Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm 2004;271: 11-9. (Pubitemid 38210080)
30. Hong JY, Kim JK, Song YK, Park JS, Kim CK. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 2006;110:332-8.
31. Mutimer MN, Riffkin C, Hill JA, Glickman ME, Cyr GN. Modern ointment bases technology - II - Comparative evaluation of bases. J Am Pharm Assoc Am Pharm Assoc. 1956;45:212-8.
32. Jain S, Padsalg BD, Patel AK, Mokale V. Formulation, development and evaluation of Fluconazole gel in various polymer bases. Asian J Pharm 2007;1:63-8.
33. Gupta GD, Gaud RS. Release rate of Tenoxicam from acrypol gels. The Ind Pharm 2005;30:69-76.
34. Gupta GD, Gaud RS. Release rate of Nimesulide from diff erent gellants. Indian J Pharm Sci 1999;61:227-30.
35. Chakole CM, Shende MA, Khadatkar SN. Formulation and development of novel combined halobetasol propionate and fusidic acid ointment. Int J Chem Tech Res 2009;1:103-16.
36. Draize J, Woodard G, Calvery H. Methods for the study of irritation and toxicity of substances topically applied to skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377-90.
37. Verneer BJ. Skin irritation and sensitization. J Control Release 1991;15:261-5.
38. Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib. Drug Dev Ind Pharm 2006;32:911-8. (Pubitemid 44359752)
39. Jung H, Kim HM, Choy YB, Hwang SJ, Choy JH. Laponite-based nanohybrid for enhanced solubility and controlled release of itraconazole. Int J Pharm 2008;349:283-90. (Pubitemid 350299711)
40. Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci 1962;51:802-4.
41. Higuchi WI, Bernardo PD, Mehta SC. Polymorphism and drug availability. II. Dissolution rate behaviour of the polymorphic forms of sulfathiazole and methylprednisolone. J Pharm Sci 1967;56:200-7.
42. Schmolka IR. Artifi cial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972;6:571-82.
43. Mundada AS, Shrikhande BK. Controlled release gel of Ciprofloxacin HCl for Ophthalmic administration. Indian Drugs 2006;43:9-12.
44. Chi SC, Jun HW. Release rate of Ketoprofen from Polaxomer Gels in a membrane less diff usion cell. J Pharm Sci 1991;80:281-3.
45. Ibrahim SA, Hafez E, Gibally IS. Bulletin of Pharmaceutical Sciences, (Assiut University-Egypt), Part I, 1991;14,1-5.
46. Foroutan SM, Hossein-Ali E, Torabi HR. Formulation and In vitro Evaluation of Silver Sulfadiazine Spray. Iranian Journal of Pharmaceutical Research 2002;1:47-9.
47. Bou-Chacra NA, Gobi SS, Ohara MT. Antimicrobial activity of four diff erent dental gel formulas on cariogenic bacteria evaluated using the linear regression method. Brazilian J Pharm Sci 2005;41:323-31. (Pubitemid 43251186)
48. El laithy HM, El-Shaboury KM. The Development of Cutina Lipogels and Gel Microemulsion for Topical Administration of Fluconazole. AAPS PharmSci Tech 2002;3:1-9.
49. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
50. Lapasin R, Grassi M, Coceani N. Eff ects of polymer addition on the rheology of o/w microemulsion. Rheo Acta 2001;40:185-92. (Pubitemid 32270494)
51. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for dermal delivery of estradiol. Int J Pharm 2003;254:88-107.
52. Spiclin P, Homar M, Zupancic-Valant A. Sodium ascorbyl phosphate in dermal microemulsion. Int J Pharm 2003;256:65-73. (Pubitemid 36412140)
53. Valenta C, Schultz K. Influence of carrageenan on the rheology and skin permeation of micromeulion formulations. J Control Rel 2004;95:257-65. (Pubitemid 38230040)
54. Rowe RC, Sheskey PJ, Weller PJ. Poloxamer. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of Pharmaceutical Excipients. Pharmaceutical Press, London, UK, 2003. p. 447-448.
55. Moore T, Croy S, Mallapragada S, Pandit N. Experimental investigation and mathematical modelling of Pluronic F127 gel dissolution: Drug release in stirred systems. J Control Release 2000;67:191-202. (Pubitemid 30303834)
56. Ilango R, Kavimani K, Kumar S, Deepa KR, Jaykar B. Formulation and evaluation of transdermal preparations of nimesulide gel. East Pharm 1998;41:123-5.
57. Miyazaki S, Takecuchi S, Yokouchi C, Takada M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem Pharm Bull (Tokyo) 1984;32:4205-8. (Pubitemid 15208373)